In vitro and in vivo evaluation of isatin-β-thiosemicarbazone and marboran against vaccinia and cowpox virus infections
- 29 March 2006
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 71 (1) , 24-30
- https://doi.org/10.1016/j.antiviral.2006.02.010
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Mechanism of Inhibition of Vaccinia Virus DNA Polymerase by Cidofovir DiphosphateAntimicrobial Agents and Chemotherapy, 2005
- An Isatin-β-thiosemicarbazone-resistant Vaccinia Virus Containing a Mutation in the Second Largest Subunit of the Viral RNA Polymerase Is Defective in Transcription ElongationJournal of Biological Chemistry, 2004
- Topical Cidofovir Is More Effective than Is Parenteral Therapy for Treatment of Progressive Vaccinia in Immunocompromised MiceThe Journal of Infectious Diseases, 2004
- Efficacy of Multiple- or Single-Dose Cidofovir against Vaccinia and Cowpox Virus Infections in MiceAntimicrobial Agents and Chemotherapy, 2003
- Effect of N,N′-bis(methylisatin-β-thiosemicarbazone)-2-methylpiperazine on vaccinia virus replicationin vitro andin vivoArchiv für die gesamte Virusforschung, 1979
- CLINICAL EXPERIENCE WITH THE ANTIVIRAL DRUG MARBORAN® (1‐METHYLISATIN 3‐THIOSEMICARBAZONE) *Annals of the New York Academy of Sciences, 1965
- MONOCYCLIC THIOSEMICARBAZONES AS ANTIVIRAL AGENTSAnnals of the New York Academy of Sciences, 1965
- PROPHYLACTIC TREATMENT OF SMALLPOX CONTACTS WITH N-METHYLISATIN β-THIOSEMICARBAZONE (COMPOUND 33T57, MARBORAN)The Lancet, 1963
- Eczema Vaccinatum Treated with N-Methylisatin -ThiosemicarbazoneBMJ, 1962
- NEW ANTIVIRAL CHEMOTHERAPEUTIC AGENT ACTIVE AGAINST SMALLPOX INFECTIONThe Lancet, 1960